» Articles » PMID: 16896182

Chronic Inhibition of Nuclear Factor-kappaB Attenuates Renal Injury in the 5/6 Renal Ablation Model

Overview
Specialties Nephrology
Physiology
Date 2006 Aug 10
PMID 16896182
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies indicated that the nuclear transcription factor, NF-kappaB, activates a number of proinflammatory genes in subjects with progressive nephropathies. We investigated whether NF-kappaB inhibition limits progressive renal injury in the 5/6 renal ablation model (Nx). Adult male Munich-Wistar rats were subdivided in four groups: S (n = 16), subjected to sham operation; S+PDTC (n = 18), sham-operated rats receiving the NF-kappaB inhibitor pyrrolidine-dithiocarbamate (PDTC; 60 mg x kg(-1) x day(-1)) in drinking water; Nx (n = 16), Nx rats receiving vehicle only; and Nx+PDTC (n = 19), Nx rats given PDTC as above. Thirty days after renal ablation, Nx rats exhibited systemic and glomerular hypertension. Only the former was attenuated by PDTC treatment. Sixty days after renal ablation, Nx rats exhibited marked hypertension, albuminuria and creatinine retention, as well as glomerulosclerosis and cortical interstitial expansion/inflammation. Immunohistochemical analysis of Nx rats showed renal interstitial infiltration by macrophages and by cells staining positively for ANG II and its receptor, AT(1). Glomerular and interstitial cells expressing the p65 subunit of the NF-kappaB system were also found. PDTC treatment attenuated renal injury and inflammation, as well as the density of cells staining positively for the p65 subunit. Activation of the NF-kappaB system plays an important role in the pathogenesis of renal injury in the Nx model. Inhibition of this system may represent a new strategy to prevent the progression of chronic kidney disease.

Citing Articles

Apocynin and Hyperbaric Oxygen Therapy Improve Renal Function and Structure in an Animal Model of CKD.

Vukovic A, Karanovic D, Mihailovic-Stanojevic N, Miloradovic Z, Brkic P, Zivotic M Biomedicines. 2025; 12(12.

PMID: 39767695 PMC: 11673868. DOI: 10.3390/biomedicines12122788.


NF-κB in biology and targeted therapy: new insights and translational implications.

Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M Signal Transduct Target Ther. 2024; 9(1):53.

PMID: 38433280 PMC: 10910037. DOI: 10.1038/s41392-024-01757-9.


Macrophage Function Modulated by tPA Signaling in Mouse Experimental Kidney Disease Models.

Lin L, Hu K Int J Mol Sci. 2023; 24(13).

PMID: 37446244 PMC: 10342253. DOI: 10.3390/ijms241311067.


Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway.

Gui T, Chen Q, Li J, Lu K, Li C, Xu B Front Pharmacol. 2023; 14:1092475.

PMID: 37033627 PMC: 10079923. DOI: 10.3389/fphar.2023.1092475.


Bolstering the secretion and bioactivities of umbilical cord MSC-derived extracellular vesicles with 3D culture and priming in chemically defined media.

Kim J, Rhim W, Cha S, Woo J, Lee J, Park C Nano Converg. 2022; 9(1):57.

PMID: 36534191 PMC: 9761620. DOI: 10.1186/s40580-022-00349-z.